Italy’s Alfasigma to purchase Intercept Pharmaceuticals for $794m
Intercept is engaged in developing and commercialising novel therapeutics for rare and serious liver diseases, and its acquisition…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
27 Sep 23
Intercept is engaged in developing and commercialising novel therapeutics for rare and serious liver diseases, and its acquisition…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
25 Sep 23
Chime Biologics and Panolos Bioscience have entered into a global strategic collaboration agreement on a novel multi-specific protein…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
21 Sep 23
Under the licensing agreement, RefleXion will develop and commercialise RXM-4768 molecule to direct its SCINTIX biology-guided radiotherapy
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
19 Sep 23
CEPI will contribute up to $90m funding for the partnership, which will support the development of mRNA-based vaccine…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
13 Sep 23
The money raised from the Series B extension will be used by ROME to advance its LINE-1 reverse…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
13 Sep 23
Through the acquisition, the French firm adds VERT-002, a monoclonal antibody that targets and degrades c-MET, which is…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
11 Sep 23
The financing is expected to drive Grit Biotechnology’s Phase 2 trial for GT101 and further development of next-generation…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
07 Sep 23
With the transaction, Kriya now own Tramontane’s FGF21 assets, including the latter’s adeno-associated virus (AAV) vector programme, designed…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
06 Sep 23
Abacavir/dolutegravir/lamivudine is a fixed-dose combination that consists of a pair of nucleoside reverse transcriptase inhibitors (NRTIs) and integrase…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
04 Sep 23
The consent order agreement with FTC allows Amgen to complete its proposed $27.8bn acquisition of Horizon Therapeutics, while…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates